Ensysce Biosciences Inc (NASDAQ: ENSC) is a clinical-stage pharmaceutical company developing abuse-deterrent and overdose-protection drug candidates targeting the opioid epidemic. The company generates no product revenue, funding operations through equity offerings, warrant exercises, and senior secured convertible promissory notes. Its lead clinical-stage candidate is PF614, an abuse-deterrent formulation of oxycodone, with additional preclinical programs including an overdose-protection compound. A 79.2%-owned subsidiary, EBIR, Inc. (formerly Covistat, Inc.), is developing a compound for COVID-19 treatment that also underpins the overdose-protection program. Ensysce operates in a heavily regulated environment governed by the FDA, DEA manufacturing quotas for Schedule II opioids, and the Federal Food, Drug and Cosmetic Act. As of the 10-K filed March 30, 2026, the company had not commercialized any product and relied on external financing, including a registered direct offering completed in August 2024 that raised approximately $1.7 million in gross proceeds, plus approximately $3.4 million from a warrant inducement agreement in the same period.

Revenue model

No product revenue as of the 10-K filed March 30, 2026. Operations are financed through registered direct equity offerings, pre-funded warrants, warrant inducement agreements, and senior secured convertible promissory notes. Disclosed debt instruments include 2021 Notes ($15.9 million original principal), 2022 Notes ($8.5 million original principal), and 2023 Notes ($1.8 million original principal).

Products and services

PF614: clinical-stage abuse-deterrent oxycodone formulation (certain patents expiring 2030). Overdose-protection program compound developed within EBIR, Inc. subsidiary. Nafamostat-based compound for respiratory disease treatment (certain patents expiring 2028). All candidates are pre-commercialization as of the filing date.

Customers and end markets

No commercial customers as of the 10-K filed March 30, 2026. Target end markets are pain management and opioid use disorder, with regulatory and reimbursement pathways involving FDA approval and CMS coverage policies for abuse-deterrent opioid formulations.

Value-chain role

Drug developer positioned upstream of commercialization. Relies on contract research organizations (CROs) for clinical trial oversight and contract manufacturing organizations (CMOs) for drug substance and product supply. Holds patents on product candidates and pursues third-party licensing and option agreements.

Geographic exposure

Primary regulatory focus is the United States (FDA, DEA). European patent coverage sought through the European Patent Office and European Medicines Agency. No commercial geographic revenue disclosed.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations Peers: TELIX QSAM INC. Bellerophon Therapeutics, Inc. TuHURA Biosciences Inc Cibus Inc Sonnet BioTherapeutics Holdings, Inc. CohBar, Inc. Exicure Inc Phio Pharmaceuticals Corp Unicycive Therapeutics Inc